• Publications
  • Influence
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
BACKGROUND Whether long-term suppression of replication of hepatitis B virus (HBV) has any beneficial effect on regression of advanced liver fibrosis associated with chronic HBV infection remainsExpand
  • 1,104
  • 42
  • PDF
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
CONTEXT Chronic hepatitis C virus (HCV) infection outcomes include liver failure, hepatocellular carcinoma (HCC), and liver-related death. OBJECTIVE To assess the association between sustainedExpand
  • 1,260
  • 40
  • PDF
Management of hepatitis B: 2000--summary of a workshop.
Chronic infection with the hepatitis B virus (HBV) is estimated to affect 400 million persons and to be the single most common cause of cirrhosis and hepatocellular carcinoma (HCC) worldwide. 1 TheExpand
  • 752
  • 39
  • PDF
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
BACKGROUND Chronic hepatitis C virus (HCV) infection in patients with cirrhosis is difficult to treat. In patients with chronic hepatitis C but without cirrhosis, once-weekly administration ofExpand
  • 952
  • 31
Telaprevir for previously treated chronic HCV infection.
BACKGROUND Patients with genotype 1 hepatitis C virus (HCV) who do not have a sustained response to therapy with peginterferon alfa and ribavirin have a low likelihood of success with retreatment. Expand
  • 741
  • 26
  • PDF
Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants.
BACKGROUND Primary biliary cirrhosis is a chronic granulomatous cholangitis, characteristically associated with antimitochondrial antibodies. Twin and family aggregation data suggest that there is aExpand
  • 505
  • 26
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
BACKGROUND & AIMS Treatment with adefovir dipivoxil for 48 weeks resulted in clinical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B that was lost whenExpand
  • 840
  • 23
Peginterferon alfa-2a in patients with chronic hepatitis C.
BACKGROUND Covalent attachment of a 40-kd branched-chain polyethylene glycol moiety to interferon alfa-2a results in a compound (peginterferon alfa-2a) that has sustained absorption, a slower rate ofExpand
  • 1,126
  • 22
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
BACKGROUND Adefovir dipivoxil, a nucleotide analogue, demonstrated clinically significant antiviral activity in patients with chronic hepatitis B in phase 1 and 2 clinical trials. METHODS WeExpand
  • 981
  • 20
  • PDF
Autoimmune hepatitis: Effect of symptoms and cirrhosis on natural history and outcome
Although the natural history of autoimmune hepatitis (AIH) has been characterized, little is known about patients who present asymptomatically. Consequently, whether they require immunosuppressiveExpand
  • 263
  • 20